Ametova L O, Kaliberdenko V B, Yatsenko A A, Asanova G R, Yakushev D A, Syskova E S, Goncharova A S, Shlapak M I, Nevedomskaya P V, Prutin M V, Tupikin A V, Kerimova D A
S.I.Georgievsky Medical Institute, V.I.Vernadsky Crimean Federal University, 5/7 blvd. Lenin, Simferopol 295051, Republic of Crimea, Russian Federation, e-mail:
Adv Gerontol. 2025;38(2):236-242.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Treatment of elderly patients with NHL has always been a challenge; however, treatment statistics have begun to show favorable results similar to those of younger patients with DLBCL, thanks to new treatment protocols. The aim of this study is to evaluate the impact of prognostic factors on survival and efficacy of therapy in elderly patients with DLBCL in the Republic of Crimea. This study included 87 patients diagnosed with DLBCL who were treated in the Department of Hematology and Chemotherapy of the N.A. Semashko Republican Clinical Hospital from 2008 to 2024. The mean age was 72 (65-89) years, and 13 (14,9%) patients were over 80 years old. The median follow-up time was 42 months, and 45 patients (51,7%) died during the follow-up period. The median overall survival (OS) was 55 months, and the median progression-free survival was calculated as 27 months. Sixty-three patients (72,4%) received standard therapy R-CHOP. Complete response was achieved in 46 patients (52,9%). The median survival for patients with complete response was 136 months (p<0,001); however, OS was not statistically different between elderly (>80 years) and young patients (p=0,236). According to our results, we believe that the opportunity to undergo standard therapy R-CHOP is vital for the survival of elderly patients with DLBCL.
弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤（NHL）类型。老年NHL患者的治疗一直是一项挑战；然而，由于新的治疗方案，治疗统计数据已开始显示出与年轻DLBCL患者相似的良好结果。本研究的目的是评估预后因素对克里米亚共和国老年DLBCL患者生存和治疗效果的影响。本研究纳入了87例2008年至2024年在N.A.谢马什科共和国临床医院血液学和化疗科接受治疗的DLBCL确诊患者。平均年龄为72（65 - 89）岁，13例（14.9%）患者年龄超过80岁。中位随访时间为42个月，45例患者（51.7%）在随访期间死亡。中位总生存期（OS）为55个月，中位无进展生存期计算为27个月。63例患者（72.4%）接受了标准治疗R-CHOP。46例患者（52.9%）实现了完全缓解。完全缓解患者的中位生存期为136个月（p<0.001）；然而，老年（>80岁）和年轻患者的OS在统计学上无差异（p = 0.236）。根据我们的结果，我们认为接受标准治疗R-CHOP的机会对老年DLBCL患者的生存至关重要。
